SARS-CoV-2 seroprevalence in vaccine-na ïve participants from the Democratic Republic of Congo, Guinea, Liberia, and Mali

In the four years since COVID-19 was declared a global pandemic on March 11, 2020, more than 760 million cases have been reported worldwide leading to a death toll of almost 7 million people [1]. During the first year of the pandemic, while high rates of SARS-CoV-2 infections were reported globally, initial reports suggested that infection rates were significantly lower in sub-Saharan Africa than in other parts of the world [2,3]. Subsequent studies revealed that although seroprevalence was rapidly increasing in sub-Saharan African countries during the start of the pandemic, it was estimated that less than 1% of infections were detected [4].

Source: International Journal of Infectious Diseases - February 25, 2024 Category: Infectious Diseases Authors: Laverdure Sylvain, Kazadi Donatien, Kone Kadidia, Callier Viviane, Dabitao Djeneba, Dennis Dehkontee, Haidara Mory Cherif, Hunsberger Sally, Mbaya Olivier Tshiani, Ridzon Renee, Sereti Irini, Shaw-Saliba Katy, the InVITE Study Team Source Type: research